The 1st General Assembly Meeting within the EPISTOP project took place on November 16-17, 2015 in Berlin, Germany. The meeting was moderated by dr. Bernhard Weschke. He is a pediatric neurologist at Charité – Universitätsmedizin Berlin. Representatives of each Partner of EPISTOP project and members of the Scientific Advisory Board attended the meeting.

During this meeting, the progress and issues of each work package were presented. Successful discussions were held about various aspects of the project: recruitment of patients, sampling, protocols, scientific research, administration and dissemination. More specific issues were adressed in the clinical and the molecular group. According to the Scientific Advisory Board members EPISTOP in general is a visionary study.

Currently 65 patients are included in our study so far. We hope to enroll more patients in the next 6 months, since the recruitment period will end in June 2016.

On behalf of AMC – Academisch Medisch Centrum, host of the Steering Committee Meeting 2016 of EPISTOP project, we are delighted to inform you that this meeting will take place on the 17th and 18th of June 2016 in Amsterdam, The Netherlands.

The meeting will be attended by the leaders of the work packages. We will discuss progress in project implementation and make strategic decisions.

New patients have been included recently to EPISTOP in the Netherlands, Italy and Australia. There are together 65 patients included in EPISTOP study already

Last week new patients have been included in Belgium and Poland. In total there are 61 patients in EPISTOP now.

We are pleased to announce that two new Partners joined EPISTOP Consortium. A.R.S. Consulting s.r.l. (Rome, Italy) is experienced in technical and financial management of research projects while Lady Cilento Children’s Hospital (Brisbane, Australia) is one of the biggest hospitals in Australia with excellent specialists experienced in TSC.

We look forward to develop successful cooperation within extended EPISTOP Consortium!